Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat
- PMID: 17963025
- DOI: 10.1007/s10928-007-9073-1
Early identification of drug-induced impairment of gastric emptying through physiologically based pharmacokinetic (PBPK) simulation of plasma concentration-time profiles in rat
Abstract
Inhibition of gastric emptying rate can have adverse effects on the absorption of food and nutrients. The absorption phase of the plasma concentration-time profile of a compound administered orally to pre-clinical species reflects among others, the gastric and intestinal transit kinetics, and can thus assist in the early identification of delayed gastric emptying. The purpose of this article is to demonstrate the value of Physiologically Based Pharmacokinetic (PBPK) modelling in the early identification of drug induced impairment of gastric emptying from pharmacokinetic profiles. To our knowledge, this is first time that the value of a generic PBPK model for hypothesis testing has been demonstrated with examples. A PBPK model built in-house using MATLAB package and incorporating absorption, metabolism, distribution, biliary and renal elimination models has been employed for the simulation of concentration-time profiles. PBPK simulations of a few compounds that are currently in drug discovery projects show that the observed initial absorption phase of their concentration-time profiles in rat were consistent with reduced gastric emptying rates. The slow uptake of these compounds into the systemic circulation is reflected in their pharmacokinetic profiles but it is not obvious until PBPK simulations are done. Delayed gastric emptying rates of these compounds in rats were also independently observed in x-ray imaging. PBPK simulations can provide early alerts to drug discovery projects, besides aiding the understanding of complex mechanisms that determine the lineshapes of pharmacokinetic profiles. The application of PBPK simulations in the early detection of gastric emptying problems with existing data and without the need to resort to additional animal studies, is appealing both from an economic and ethical standpoint.
Similar articles
-
Identification of intestinal loss of a drug through physiologically based pharmacokinetic simulation of plasma concentration-time profiles.Clin Pharmacokinet. 2008;47(4):245-59. doi: 10.2165/00003088-200847040-00003. Clin Pharmacokinet. 2008. PMID: 18336054
-
Evaluation of a generic physiologically based pharmacokinetic model for lineshape analysis.Clin Pharmacokinet. 2008;47(4):261-75. doi: 10.2165/00003088-200847040-00004. Clin Pharmacokinet. 2008. PMID: 18336055
-
Evaluation of Physiologically Based Pharmacokinetic Models to Predict the Absorption of BCS Class I Drugs in Different Pediatric Age Groups.J Clin Pharmacol. 2021 Jun;61 Suppl 1:S94-S107. doi: 10.1002/jcph.1845. J Clin Pharmacol. 2021. PMID: 34185902
-
Ethanol-drug absorption interaction: potential for a significant effect on the plasma pharmacokinetics of ethanol vulnerable formulations.Mol Pharm. 2009 Sep-Oct;6(5):1429-40. doi: 10.1021/mp9000876. Mol Pharm. 2009. PMID: 19655809 Review.
-
PBPK models for the prediction of in vivo performance of oral dosage forms.Eur J Pharm Sci. 2014 Jun 16;57:300-21. doi: 10.1016/j.ejps.2013.09.008. Epub 2013 Sep 21. Eur J Pharm Sci. 2014. PMID: 24060672 Review.
Cited by
-
To scale or not to scale: the principles of dose extrapolation.Br J Pharmacol. 2009 Jul;157(6):907-21. doi: 10.1111/j.1476-5381.2009.00267.x. Epub 2009 Jun 5. Br J Pharmacol. 2009. PMID: 19508398 Free PMC article. Review.
-
Requirements to Establishing Confidence in Physiologically Based Pharmacokinetic (PBPK) Models and Overcoming Some of the Challenges to Meeting Them.Clin Pharmacokinet. 2019 Nov;58(11):1355-1371. doi: 10.1007/s40262-019-00790-0. Clin Pharmacokinet. 2019. PMID: 31236775 Free PMC article.
-
Quantitative in vitro-to-in vivo extrapolation of human adrenergic and trace amine-associated receptor 1 potencies of pre-workout supplement ingredients using physiologically based kinetic modelling-based reverse dosimetry.Arch Toxicol. 2025 May;99(5):1999-2021. doi: 10.1007/s00204-025-03992-7. Epub 2025 Apr 3. Arch Toxicol. 2025. PMID: 40178592 Free PMC article.
-
Assessing drug distribution in tissues expressing P-glycoprotein using physiologically based pharmacokinetic modeling: identification of important model parameters through global sensitivity analysis.J Pharmacokinet Pharmacodyn. 2009 Dec;36(6):495-522. doi: 10.1007/s10928-009-9134-8. Epub 2009 Oct 22. J Pharmacokinet Pharmacodyn. 2009. PMID: 19847628
-
Systems pharmacology models can be used to understand complex pharmacokinetic-pharmacodynamic behavior: an example using 5-lipoxygenase inhibitors.CPT Pharmacometrics Syst Pharmacol. 2013 Sep 11;2(9):e74. doi: 10.1038/psp.2013.49. CPT Pharmacometrics Syst Pharmacol. 2013. PMID: 24026253 Free PMC article.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical